Regulatory News:
Eurofins (Paris:ERF):
This document is not for release,
publication or distribution (directly or indirectly) in or to the
United States of America, Canada, Australia or Japan. It is not an
offer of securities for sale in or into the United States, Canada,
Australia or Japan.
This document is not an offer of securities
for sale in the United States. The shares to which this document
relates have not been and will not be registered under the United
States Securities Act of 1933, as amended (the “Securities Act”),
and may not be offered or sold in the United States absent
registration or an exemption from registration under the Securities
Act. There will not be a public offering of shares in the United
States.
Eurofins Scientific (EUFI.PA) announces that it has decided not
to proceed with the contemplated placement of new shares as
communicated yesterday, the 9th of December 2015. After the
announcement at 18h00 CET, the capital market situation became, and
remained more volatile, and the management deemed that carrying out
the placement amidst unfavourable conditions would penalize its
existing shareholders disproportionately. This decision not to
proceed with the contemplated placement offer should have no impact
on Eurofins’ ability to achieve its previously communicated
objectives for the near or medium-term, and to generate value for
its shareholders, as the main goal of the offering was to increase
Eurofins’ strategic options beyond these objectives, including
acquisitions of significantly larger size than what would be
required to add only EUR 200m revenue per year. As communicated on
the 19th of October, 2015, the Group is already very well-funded to
carry out at least the first phase of the organic and acquisition
investments contemplated by its plan to reach EUR 4bn turnover by
2020.
For more information, please visit
www.eurofins.com
Notes for the editor:Eurofins – a global leader in
bio-analysisEurofins Scientific is the world leader in food,
environment and pharmaceutical products testing. It is also one of
the global market leaders in agroscience, genomics, discovery
pharmacology and central laboratory services. In addition, Eurofins
is one of the key emerging players in specialty clinical diagnostic
testing in Europe and the USA.
With 20,000 staff in around 200 laboratories across 39
countries, Eurofins offers a portfolio of over 130,000 reliable
analytical methods for evaluating the safety, identity,
composition, authenticity, origin and purity of biological
substances and products, as well as for innovative clinical
diagnostic. The Group provides its customers with high-quality
services, accurate results on time and expert advice by its highly
qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimerThis press release contains
forward-looking statements and estimates that involve risks and
uncertainties. The forward-looking statements and estimates
contained herein represent the judgement of Eurofins Scientific’
management as of the date of this release. These forward-looking
statements are not guarantees for future performance, and the
forward-looking events discussed in this release may not occur.
Eurofins Scientific disclaims any intent or obligation to update
any of these forward-looking statements and estimates. All
statements and estimates are made based on the information
available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
This document and the information contained herein is not for
publication or distribution into the United States of America and
should not be distributed or otherwise transmitted into the United
States or to U.S. persons (as defined in the U.S. Securities Act of
1933, as amended (the “Securities Act”)) or publications with a
general circulation in the United States.
This press release does not, and shall not, in any
circumstances, constitute a public offering nor an invitation in
any jurisdiction in connection with any offer.
This press release has been prepared on the basis that any offer
of the new shares in any Member State of the European Economic Area
("EEA") which has implemented the Prospectus Directive
(2003/71/EC), and in particular in the Grand Duchy of Luxembourg
and France, (each, a "Relevant Member State") will be made pursuant
to an exemption under the Prospectus Directive, as implemented in
that Relevant Member State, from the requirement to publish a
prospectus. Accordingly any person making or intending to make any
offer in that Relevant Member State of securities which are the
subject of the placement contemplated in this press release may
only do so in circumstances in which no obligation arises for
Eurofins Scientific or any of the Joint Bookrunners to publish a
prospectus pursuant to Article 3 of the Prospectus Directive, as
amended, in relation to such offer. Neither Eurofins Scientific nor
the Joint Bookrunners have authorized, nor do they authorize, the
making of any offer of the new shares in circumstances in which an
obligation arises for Eurofins Scientific or any of the Joint
Bookrunners to publish prospectus for such offer.
This press release is only being distributed to, and is only
directed at, persons in the United Kingdom that (i) are “investment
professionals” falling within Article 19(5) of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005 (as
amended, the "Order"), (ii) are persons falling within Article
49(2)(a) to (d) ("high net worth companies, unincorporated
associations, etc.") of the Order, or (iii) are persons to whom an
invitation or inducement to engage in investment activity (within
the meaning of section 21 of the Financial Services and Markets Act
2000) in connection with the issue or sale of any securities may
otherwise lawfully be communicated or caused to be communicated
(all such persons together being referred to as "relevant
persons"). This press release is directed only at relevant persons
and must not be acted on or relied on by persons who are not
relevant persons. Any investment or investment activity to which
this press release relates is available only to relevant persons
and will be engaged in only with relevant persons.
This press release is an advertisement and not a prospectus for
the purposes of applicable measures implementing Directive
2003/71/EC, as amended.
This press release is not an offer of securities for sale nor
the solicitation of an offer to purchase securities in the United
States of America or any other jurisdiction. Securities may not be
offered or sold in the United States of America absent registration
or an exemption from registration under the U.S. Securities Act of
1933, as amended. Eurofins Scientific does not intend to register
any portion of a potential offering in the United States of America
or to conduct a public offering of securities in the United States
of America.
It may be unlawful to distribute these materials in certain
jurisdictions. These materials are not for distribution in Canada,
Japan or Australia. The information in these materials does not
constitute an offer of securities for sale in the United States,
Canada, Japan or Australia.
Each of BNP Paribas, Deutsche Bank AG, London Branch and J.P.
Morgan Securities plc is acting on behalf of Eurofins Scientific
and no one else in connection with any offering of the shares and
will not be responsible to any other person for providing the
protections afforded to any of its clients or for providing advice
in relation to any offering of Eurofins Scientific shares.
The Joint Bookrunners involved in the Placement and certain of
their affiliates, have provided and may in the future provide
various financing, banking, financial, investment, commercial or
other services to Eurofins Scientific or to members of its group,
in exchange for which they have received or may receive
compensation.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151210005868/en/
Eurofins Investor RelationsPhone: +32-2-766 1620E-mail:
ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024